Clinical analysis of 66 cases with orbital apex syndrome: a case series Authors: Zhonghua Ma, Hanqiu Jiang, Shilei Cui, Jingting Peng, Jiawei Wang Published: 2026 ABSTRACT AbstractBackgroundOrbital apex syndrome (OAS) is a rare ocular complication characterized by vision loss and ophthalmoplegia from infection, inflammation, trauma, neoplasms, and vascular causes, due to the involvement of ocular motor nerves in the anatomical region of the orbital apex. The epidemiological features of OAS are limited. Therefore, this study aimed to present the clinical features and determine the causes to evaluate the visual prognosis of patients with OAS.MethodsA retrospective analysis was conducted on 126 adult patients with clinically confirmed OAS by reviewing the electronic medical records from Beijing Tongren Hospital, Capital Medical University, Beijing, China, between January 2020 and December 2024. Data on demographic information, clinical findings, medical history, laboratory results, radiological findings, diagnosis, treatment, and prognosis were collected. The final cohort comprised 66 patients with OAS (mean age: 54.95 ± 18.48 years; male: 36.36% and female 63.64%).ResultsAll patients presented with unilateral involvement: 25 with right OAS and 41 with left OAS. However, the initial ocular presentations varied: blurred vision was reported in all patients, with 63.64% of them suffering from severe visual function impairment (best-corrected visual acuity, BCVA < 20/200), followed by ophthalmoplegia in 56 patients (84.85%), and headache/facial numbness in 40 patients (60.61%). Inflammation (54.55%) was the most frequent cause for OAS, followed by neoplasm (18.18%), trauma (15.15%), and infection (9.09%). After treatments, we found that the vision of 26 patients (39.39%) improved, the vision of 38 patients (57.58%) remained stable, and the vision of 2 patients (3.03%) worsened to blindness. The mortality in three patients was attributed to the underlying malignancies. Further subgroup analysis revealed that the proportion of patients with BCVA < 20/200 was significantly lower in the inflammatory group compared with the non-inflammatory group (27.78% vs. 66.67%, P = 0.002) after treatments. In the comparison between the inflammatory subgroup and the neoplastic subgroup, we found tha the patients in the inflammatory group were significantly younger than those in the neoplastic group (P = 0.015), the course of disease was significantly shorter (P = 0.020), and the proportion of severe visual function impairment (BCVA < 20/200) was significantly lower in the inflammatory group than in the neoplastic group (27.78% vs. 66.67%, P = 0.036). After adjusting for other confounding factors, etiology was an independent influencing factor for patient improvement (OR = 2.345, 95% CI: 1.126–4.881, P = 0.023).ConclusionsThe clinical manifestations and etiologies of OAS are heterogeneous. Patients with OAS suffer from severe impairment of visual function, even after undergoing aggressive and comprehensive treatment. Our findings indicated that the inflammation was the most frequent cause of OAS and correlated with better visual outcomes.Clinical trial numberNot applicable.Keywords: Inflammation, Orbital apex syndrome, Retrospective case series, Visual impairment Background Orbital apex syndrome (OAS) is the general term for specific clinical manifestations caused by various lesions invading the orbital apex, defined as a collection of dysfunctions involving multiple cranial nerves (CNs), including the optic nerve (II), oculomotor nerve (III), trochlear nerve (IV), abducens nerves (VI), and the first branch of trigeminal nerve (V1), as shown in Fig. 1. OAS is an uncommon disorder characterized by visual loss, ophthalmoplegia, headache, and hypoesthesia of the forehead [1]. OAS may result from a variety of inflammatory [2], infectious [3–5], neoplastic [6, 7], and vascular conditions [8] causing damage to the optic canal, superior orbital fissure, or cavernous sinus. Clinical evaluations include certain serological investigations, neuroimaging modalities including brain and orbital magnetic resonance imaging (MRI) with contrast, and computed tomography (CT) scans with contrast. In rare instances, a biopsy may be needed to aid in diagnosis. OAS can be life-threatening in the case of disease invasion leading to intracranial involvement. Without adequate clinical knowledge regarding neuro-ophthalmology, OAS may be misdiagnosed, resulting in delayed treatment, serious loss of function, or even death. The severity and prognosis of OAS vary widely due to the large variety of disease conditions. Given the lack of data regarding the ophthalmic presentations of patients with OAS in the Chinese population, we aimed to explore the clinical characteristics, etiology, and prognosis of OAS, with the aim to enhance the understanding of this disease, facilitate early diagnosis and treatment, and improve patient prognosis. Orbital MRI of a 70-year-old female patient with OAS. Abnormal signal intensity with abnormal enhancement was observed in the left orbital apex, cavernous sinus, and pterygomaxillary fossa on contrast-enhanced T1-weighted imaging with fat-suppressed sequences. The biopsy pathology results indicated nonspecific inflammatory lesions Methods Patient enrollment This retrospective study analyzed 126 adult patients with a clinically confirmed OAS, who were managed in the Beijing Tongren Hospital, Beijing, China, between January 2020 and December 2024. It was approved by the Institutional Review Board of Beijing Tongren Hospital, Capital Medical University. A standardized protocol was employed for the review of medical records. Clinical data pertaining to signs and symptoms, medical history, ophthalmic and neurological examinations, laboratory investigations, neuroimaging results, treatment methods, and visual outcomes were documented. Furthermore, histopathologic specimens were obtained from certain patients who underwent surgical intervention. A retrospective review of clinical data was conducted at two time points: baseline visit and final follow-up. Diagnoses of OAS were re-evaluated by three neuro-ophthalmologists (Jiang Hanqiu, Cui Shilei, and Peng Jingting). In case of any disagreements in the diagnoses, the clinical data was adjudicated by reaching a consensus based on the group. Patients included in this study were diagnosed with OAS based on the classic clinical-anatomic definition and radiological confirmation, as previously described [1, 9, 10]. The inclusion criteria were defined as follows: (1) Presence of optic nerve (CN Ⅱ) dysfunction, manifesting as visual loss, visual field defect, or relative afferent pupillary defect (RAPD); (2) Concurrent involvement of any combination of cranial nerves Ⅲ, Ⅳ, Ⅵ (presenting with ophthalmoplegia, ptosis, or fixed eyeball) and/or CN V₁ (presenting with sensory disturbance in the forehead, upper eyelid, or nasal bridge); (3) Radiological evidence of lesions localized to the orbital apex, confirmed by orbital computed tomography (CT) or magnetic resonance imaging (MRI). The exclusion criteria were: (1) Isolated optic nerve dysfunction without involvement of CN Ⅲ, Ⅳ, Ⅵ, or V₁; (2) Diagnosis of superior orbital fissure syndrome (only CN Ⅲ, Ⅳ, Ⅵ, V₁ involvement without optic nerve damage); (3)Evidence of cavernous sinus involvement (e.g., CN V₂ palsy, severe ocular congestion, or clinical manifestations of cavernous sinus thrombosis); (4) Isolated single cranial nerve palsy without combined cranial nerve involvement; (5) Absence of radiological confirmation of orbital apex lesions; (6) Incomplete clinical data (lack of visual field test, RAPD assessment, or detailed cranial nerve examination records; (7) Loss to follow-up; (8) Lack of informed consent. The final cohort comprised 66 eligible patients. The follow-up period of these patients ranged from 11 months to 23 months, with a mean of 14.2 (standard deviation: 9.1) months. Further, 60 patients were excluded from this retrospective observation: 27 due to incomplete neuroimaging, 22 owing to loss to follow-up after diagnosis, and 11 due to the lack of informed consent (Fig. 2). Flowchart of OSA patient enrolment Visual examinations The BCVA was assessed using the Snellen visual acuity chart. Visual impairment was categorized as severe (BCVA < 20/200), moderate (20/200 ≤ BCVA ≤ 20/50), or mild (BCVA ≥ 20/40). A visual acuity worse than 20/200 was deemed poor in this study. Visual field (VF, humphrey field) testing was performed for all patients VF results were independently evaluated by two neuro-ophthalmologists according to the MD-based grading scale proposed by Shah et al. [8], as follows: Grade 0, normal VF; Grade 1, MD < 4.0 with presence of a VF defect; Grade 2, MD 4.0–11.9; Grade 3, MD 12.0–19.9; and Grade 4, MD > 20.0. Tests demonstrating unreliable autoperimetry results, defined by false-negative/false-positive errors exceeding 20%, were excluded from the analysis. Statistical analysis Statistical analyses were performed using SPSS version 24.0. Categorical data were presented as numbers and percentages, whereas continuous data were expressed as mean ± standard deviation. Comparisons of continuous data were conducted using the independent-samples t test or the Mann-Whitney U test, as appropriate. Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test. A two-tailed P value of less than 0.05 indicated a statistically significant difference. Correlations between visual outcome and baseline variables were analyzed using Pearson or Spearman correlation. Univariate and multivariate logistic regression analyses were conducted to identify independent factors associated with visual function recovery. Results were expressed as odds ratios (OR) with 95% confidence intervals (95% CI). Results Patient characteristics We included 66 patients with OAS [mean age 54.95 ± 18.48 years; 24 male (36.36%) and 42 female (63.64%)] in this study, as shown in Table 1. The median course of duration before presentation was 1.89 ± 0.72 months, and 1.77 ± 0.89 months for patients with inflammatory OAS. Table 1Clinical characteristics of patients in our case seriesCharacteristicNumber (n = 66)PercentageSexMale2436.36%Female4263.64%LateralityRight2537.88%Left4162.12%Symptoms/SignVisual loss66100%Ophthalmoplegia5684.85%Headache2436.36%Facial numbness1624.24%Diagnostic imagingMRI6192.42%MRI + CT4365.15%Pathological biopsyYes2842.42%No3857.58%Visual prognosisImproved2639.39%Stable3857.58%Worsened23.03% Clinical characteristics of patients in our case series Clinical manifestations Symptoms: All patients presented with single-eye involvement of OAS, with varying degrees of decreased vision on the affected side. On initial presentation, these patients exhibited various clinical manifestations shown in Table 1. The most common manifestation was blurred vision (100%), followed by ophthalmoplegia in 56 patients (84.85%), headache in 24 patients (36.36%), and forehead/facial numbness in 16 patients (24.24%). Six patients with infectious diseases had fever, and one with intracranial gungal infection presented with impairment of consciousness. Physical signs: All 66 patients exhibited unilateral visual loss. The initial BCVA of these patients ranged from no light perception (NLP) to 20/25. Further, 63.64% of the patients had a visual acuity worse than 20/200 upon presentation, as shown in Table 2. Of these, 9 patients had NLP. Positive RAPD were detected in 48 patients (72.73%). Also, 21 patients (31.82%) had papilledema and venous dilation in the fundus. Optic nerve atrophy was observed in 5 patients with chronic-onset neoplasm lesions. The limitation of extraocular movement was observed in 84.85% of the patients. The ophthalmic division of CN V was impacted in 11 (16.67%) patients. Ocular hypertension was recorded in 17 patients (25.77%). Among 10 patients with traumatic diseases, 8 exhibited wounds and swelling on the external surface of the injured eye, 3 had wounds on the forehead on the injured side, and 2 had cerebrospinal fluid leakage from the nose. Table 2BCVA at presentation and at final visitBCVAInitialFinalP valueAll patients (66)<20/20042, 63.64%30, 45.45%0.03620/200–20/5016, 24.24%11, 16.67%≥ 20/408, 12.12%25, 37.88%Inflammation-induced (36)<20/20020, 55.56%10, 27.78%0.01720/200–20/509, 25%8, 22.22%≥ 20/407, 19.44%18, 50%Non-inflammation (30)<20/20022, 73.33%20, 66.66%0.13520/200–20/507, 23.33%3, 10%≥ 20/401, 3.33%7, 23.33% BCVA at presentation and at final visit Laboratory tests Blood test The blood routine examination revealed neutrophilia in 12 patients, of whom 6 had infectious diseases, 3 had traumatic disease, and 3 had nonspecific inflammatory diseases. Elevated C-reactive protein levels were observed in 49 patients. Elevated antineutrophil cytoplasmic antibodies (ANCA) levels were noted in four cases. Serum immunoglobulin G4(IgG4) levels were elevated in two patients. No significant abnormalities were found in other blood inflammatory indicators, such as serum angiotensin-converting enzyme(ACE) level, double-stranded DNA antibody(dsDNA), antinuclear antibody(ANA), and extractable nuclear antigen antibodies(ENA). Changes in cerebrospinal fluid Lumbar puncture (LP) may be considered in selected cases. It can aid diagnosis in infectious conditions and neoplastic diseases such as lymphomas, leukemias, and meningeal infiltration. In our study, the cerebrospinal fluid (CSF) was examined in all these cases. Abnormal results were found in 14 patients, all exhibiting elevated CSF protein levels. Among these, 12 also had elevated CSF white blood cell counts (predominantly monocytes). However, glucose and chloride levels were normal. Tissue biopsy. A total of 28 patients underwent tissue biopsy for definitive diagnosis. The histopathologic results showed inflammatory disease in 12 patients, fungal infection in 6 patients, and neoplasm in 10 patients. Neurological imaging A total of 61 patients underwent contrast-enhanced MRI of the brain and orbits, including T1-weighted and T2-weighted fat-suppressed sequences, 5 patients CT only, and 43 patients both CT and MRI. All patients presented with lesions in the orbital apex region: 32 cases manifested as diffuse swelling accompanied by bone destruction, 26 cases manifested as diffuse swelling without bone destruction and 8 cases with localized lesions, as shown in Table 3. Positron emission tomography(PET)was performed in 13 patients and 1 case with metastatic tumor was confirmed by PET. Digital subtraction angiography (DSA) was performed in 10 patients and 2 cases with carotid-cavernous fistula(CCF) were conformed. All image examinations were independently reviewed by an neuroradiologist (Ma Zhonghua) and two neurologists (Peng Jingting and Wang Jiawei). All patients were diagnosed by imaging examinations along with a comprehensive systemic work-up and detailed medical records. Among these, 47 patients underwent orbital MRI re-examination during the follow-up period (Fig. 3). Table 3Comparison of clinical information of OSA with different EtiologiesInflammation(n = 36)Neoplasm(n = 12)P valueTrauma(n = 10)Infection(n = 6)CCF(n = 2)Sex male11,30.56%4,33.33%7,70.00%1,16.67%1,50.00%femle25,69.44%8,66.67% 1.00 3,30.00%5,83.33%1,50.00%Age(years)55.29 ± 15.0466 ± 13.23 T-2.624, P = 0.015. 30.60 ± 8.8267.5961.20Duration before treatment(months)1.77 ± 0.893.25 ± 1.21Z- = 2.331P = 0.0200.30 ± 0.112.52Symptoms Visual impairment36,100%12,100%10,100%6,100%2,100%Ophthalmoplegia31,86.11%9,25.00% 0.394 9,90.00%5,83.33%2,100%Headache6,16.67%4,33.33% 0.241 10,100%3,50.00%1,50.00%Facial numbness9,25%2,16.67% 0.705 2,20.00%2,33.33%1,50.00%BCVA at baseline (< 20/200)20,55.56%9,75% 0.316 7,70.00%5,83.33%1,50.00%BCVA at follow-up(< 20/200)10,27.78%8,66.67% 0.036 6,60.00%5,83.33%1,50.00%Imaging on MRI/CT Diffuse swellingwith bone destruction17,47.2%10,83.3%0.02941Diffuse swellingwithout bone destruction12,33.33%2,16.7%0.465102Footnote BCVA best-corrected visual acuity CCF, carotid-cavernous fistula; OAS, orbital apex syndrome Comparison of clinical information of OSA with different Etiologies Z- = 2.331 P = 0.020 Imaging on MRI/CT Diffuse swelling with bone destruction Diffuse swelling without bone destruction Footnote BCVA best-corrected visual acuity CCF, carotid-cavernous fistula; OAS, orbital apex syndrome Orbital MRI of a 34-year-old female patient with right-sided OAS caused by inflammation on T1-weighted contrast-enhanced imaging with fat-suppressed sequences. The two images on the left are in the initial stage. The two images on the right show improvement after treatment (corticosteroid therapy for 3 months) Etiology of OAS Among the 66 patients, inflammation was the leading cause of OAS accounting for 54.54% (36/66), followed by neoplasm accounting for 18.18% (12/66), trauma-related causes, accounting for 15.15% (10/66), infectious causes(fungal infection) accounting for 9.09% (6/66), and vascular causes(CCF)accounting for 3.03% (2/66). Inflammation (36 patients, 54.55%) was the most frequent cause for OAS in this cohort, of which 12 were diagnosed by a histopathology examination and 24 by typical imaging with a comprehensive systemic work-up and detailed medical history review. Among the inflammatory lesions, 15 patients were diagnosed with Tolosa-Hunt syndrome (THS), 15 with nonspecific inflammation, 4 with ANCA-related vasculitis, and 2 with IgG4-related variant form. Among the 12 patients with neoplastic causes, 10 were diagnosed by a histopathology examination and 2 by typical imaging only. The neoplasms leading to OAS observed in our study were found to be malignant in 83.33% (10/12) of patients(4 olfactory neuroblastoma, 3 adenoid cystic carcinoma and 3 diffuse large B cell lymphoma), with 2 meningiomas considered benign. Among the 10 patients with traumatic diseases, 6 were diagnosed with multiple orbital fractures and 4 with eyeball contusion. 6 patients with infectious diseases were diagnosed with fungal sinusitis confirmed by histopathologic exams. Two patients with vascular causes diseases were diagnosed with carotid-cavernous fistula (CCF), which was confirmed by DSA. Treatment Treatment is directed toward the definite etiology and medical conditions of patients. Inflammatory causes were treated with systemic immunomodulatory agents: glucocorticoids were the core treatment. For severe cases (manifested as severe orbital pain, complete ophthalmoplegia, significant visual loss [BCVA < 20/200], optic nerve severe edema on imaging), high-dose intravenous glucocorticoid pulse therapy (with a dose of intravenous 1 g of methylprednisolone for 3–5 consecutive days, followed by oral prednisolone at a dose of 1 mg/kg of body weight with slow tapering) was initiated, combined with immunosuppressants (methotrexate or azathioprine) or biological agents (for patients with glucocorticoid intolerance), and orbital decompression surgery is considered if the optic nerve compression were severe and the symptoms are not relieved after medical treatment. For moderate cases high-dose oral glucocorticoids(prednisolone at a dose of 1 mg/kg) or low-dose intravenous pulse therapy(0.25 g of methylprednisolone for 3–5 consecutive days) were adopted, if the symptoms are not relieved within 1–2 weeks, immunosuppressants (such as methotrexate or azathioprine) were added to enhance the anti-inflammatory effect. For mild cases oral glucocorticoids (e.g., prednisone at a dose of 1 mg/kg of body weight) were used for symptomatic treatment, combined with neurotrophic drugs to promote nerve function recovery, and the dosage is gradually reduced after symptom remission. The treatment effects were closely monitored. Of these, 12 patients were treated with optic canal decompression. Neoplastic causes were treated with surgical resection, chemotherapy, or radiotherapy.All six patients with fungal infections received antifungal treatments such as fluconazole and amphotericin B. Vascular causes (CCF) were treated with endovascular embolization. Clinical outcome After various treatments aimed at the underlying etiologies, all patients with headache and extraocular muscle paralysis, such as diplopia and ptosis, experienced different degrees of improvement. the vision of 2 patients (3.03%) with fungal infection worsened to blindness.The mortality in three patients was attributed to the underlying malignancies. No recurrent cases were documented throughout the entire follow-up period. Visual prognosis BCVA After treatments aimed at the underlying etiologies, 26 patients (39.39%) had improved BCVA, 38 (57.58%) had stable BCVA, and 2 cases (3.03%) had worsened BCVA. The initial BCVA at diagnosis ranged from NLP to 20/25. Forty-two patients (63.64%) had a visual acuity worse than 20/200 (9 patients with NLP), 16 patients (24.24%) had moderate visual impairment (20/200 ≤ BCVA ≤ 20/50), and 8 patients (12.12%) had BCVA better than 20/40 (Table 2). The visual acuity at the final follow-up visit ranged from NLP to 20/20. Thirty patients (45.45%) had a BCVA < 20/200 (6 patients with NLP), 11 patients (16.67%) had moderate visual impairment, and 25 patients (37.88%) had BCVA better than 20/40. In patients with a final BCVA < 20/200, the inflammatory causes accounted for 33.33% (10 patients, Table 2), whereas the proportion was 47.62% (20/42) before treatments. BCVA of 17 patients (47.22%) with inflammatory OAS improved after treatments. No significant differences were observed in the proportion of improved cases between the inflammation group and the entire group (47.22% vs. 39.39%, P = 0.444). Also, no difference was found in the proportion of patients with BCVA < 20/200 between the inflammatory group and the entire group in the initial stage (55.56% vs. 63.64%, P = 0.424). The statistical analysis using Pearson’s chi-square test revealed that the BCVA of patients with severe visual impairment (BCVA < 20/200) was significantly reduced after treatment (63.64% vs. 45.45%, P = 0.036). Meanwhile, we observed a similar trend in patients with inflammatory causes, with a significant decrease in the proportion of severe visual impairment after treatment (55.56% vs. 27.78%, P = 0.017), as shown in Table 2. Further subgroup analysis showed that the proportion of patients with BCVA ≥ 20/200 was significantly higher in the inflammatory group compared with the non-inflammation group (72.22% vs. 33.33%, P = 0.002). Our data indicated a relationship between the causes of the disease (inflammatory or non-inflammatory) and visual prognosis; inflammatory causes were correlated with better final visual acuity. Visual field Automated perimetry was performed for VF evaluation in 62 patients, demonstrating various types of VF defects: generalized depression, central scotoma, paracentral scotoma, and so on. The mean VF defect grade dropped from 2.95 ± 1.12 in the initial stage to 2.67 ± 1.17 during final follow-up, although this difference did not reach statistical significance (P = 0.317). During follow-up, mortality occurred in three patients with a malignant tumor. The intervals between the onset of OAS and mortality were 10, 11, and 12.5 months, respectively, in these patients. Optical coherence tomography (OCT) From the medical records, we extracted the pre-treatment OCT examination results of 31 patients and collected related information on the thickness of the retinal nerve fiber layer (RNFL) in the optic disc area: 23 cases were inflammatory OAS, among which 21 cases showed normal RNFL thickness and 2 cases showed thinning; 6 cases were neoplastic OAS, among which 2 cases showed normal and 4 cases showed thinning; 2 cases were infectious OAS, among which 1 case showed normal RNFL thickness and 1 case showed thinning. To investigate the effects of different RNFL changes and related factors on inflammatory patients’BCVA improvement, binary logistic regression analysis was performed in these 23 patients with OCT information. Improvement status was set as the dependent variable. Independent variables included gender, age, disease duration, RNFL thickness and baseline BCVA. After adjusting for confounding factors, gender (P = 0.892), age (P = 0.634), disease duration (P = 0.764), baseline BCVA (P = 0.892) and RNFL thickness(P = 0.999) showed no significant effects on patient BCVA improvement. Comparism of the subgoroup (inflammation and neoplasm) Subsequently, we compared the clinical data of patients in the inflammatory subgroup and the neoplastic subgroup (Table 3). Both groups showed a high proportion of female patients, but there was no statistically significant difference in the gender ratio between the two groups (P = 1.00). We found that the patients in the inflammatory group were significantly younger than those in the neoplastic group (P = 0.015), and the course of disease was significantly shorter (P = 0.020). In terms of clinical manifestations, the incidence of headache was significantly higher in the neoplastic group than in the inflammatory group, but the difference did not reach statistical significance (33.33% vs. 16.67%, P = 0.241). In addition, the incidences of ophthalmoplegia and facial sensory disturbance were notably higher in the inflammatory group than in the neoplastic group, yet without statistical significance (P = 0.394 and P = 0.705, respectively). Regarding the visual function outcome, the proportion of severe visual impairment (BCVA < 20/200) was significantly lower in the inflammatory group than in the neoplastic group (27.78% vs. 66.67%, P = 0.036). Binary logistic regression analysis was performed to investigate the effects of different etiologies and related factors on patients’ BCVA improvement. Improvement status (0 = good, 1 = poor) was set as the dependent variable. Independent variables included etiology (1 = inflammation, 2 = neoplasm), gender (1 = male,2 = female), age, disease duration, and baseline BCVA (0 = good, 1 = poor). The results showed that the model fitted well (Hosmer–Lemeshow test: χ² = 4.256, P = 0.759), with an overall predictive accuracy of 81.3%. After adjusting for other confounding factors, etiology was an independent influencing factor for patient improvement (OR = 2.345, 95% CI: 1.126–4.881, P = 0.023). Specifically, patients with inflammatory OAS had a significantly higher probability of improvement than those with neoplasm. In contrast, gender (P = 0.356), age (P = 0.156), disease duration (P = 0.218), and baseline BCVA (P = 0.472) showed no significant effects on patient improvement. Discussion OAS refers to a constellation of symptoms and signs resulting from the involvement of various structures in the orbital apex in the disease process. The clinical manifestations of OAS include decreased vision on the affected side, ptosis, impaired ocular motility, diplopia, frontal pain, and ocular pain. The most common clinical features are vision loss and painful and limited eye movements. However, the initial symptoms, disease progression, and severity can vary from person to person, and may be related to the etiology, sequence, and extent of nerve involvement. The data on OAS related to ocular diseases are scarce and involve mostly small-scale studies, possibly due to the rarity of this disease entity [11–13] and heterogeneity of underlying etiologies requiring experienced specialists for accurate diagnosis. Our study, including 66 patients with OAS, aimed at providing a more general overview of the clinical features, etiologies, and visual prognosis of OAS. In our study, all the patients exhibited unilateral involvement of OAS. Their mean age was 54.95 ± 18.48 years, with 36 being female (63.64%). The most common complaint upon initial presentation was blurred vision reported in all patients (100%), followed by ophthalmoplegia in 56 patients (84.85%) and headache in 24 patients (36.36%). The visual function impairment of the patients in this group was severe; 63.64% of the patients had a BCVA worse than 20/200 upon presentation, of which nine patients had NLP. A large variety of pathological processes (inflammatory, infectious, or neoplastic) can impact the orbital apex. Detailed clinical examination, appropriate imaging modalities, and, sometimes, tissue biopsy for histopathological examinations are crucial for establishing an accurate diagnosis. Imaging examination is a key method for determining the location, scope, and etiology of orbital apex syndrome (OAS). Among them, orbital MRI is the preferred imaging method for diagnosing OAS due to its high soft tissue resolution, while orbital computed tomography (CT) is more suitable for displaying abnormalities of bony structures. The combined application of the two can significantly improve the diagnostic accuracy [9]. The core imaging feature of OAS is the presence of abnormal signals or structural changes in the orbital apex, accompanied by involvement of the optic nerve, superior orbital fissure, and surrounding soft tissues. The imaging manifestations of inflammatory OAS are characterized by inflammatory infiltration: diffuse swelling of the soft tissues at the orbital apex with high signal on MRI T2-weighted imaging (T2WI) sequence and uniform enhancement after contrast enhancement; while, CT examination shows increased soft tissue density at the orbital apex without obvious bone destruction. The imaging manifestations of OAS caused by neoplastic factors are mainly characterized by space-occupying lesions: blurred boundaries and irregular shapes, uneven signals, and uneven enhancement after contrast enhancement, often accompanied by obvious orbital apex bone destruction and surrounding soft tissue invasion [10, 14]. In our study, 61 patients underwent contrast-enhanced MRI scan of the brain and orbits, and 43 underwent both CT and MRI. This provided sufficient radiographic support for us to make a definitive diagnosis of OAS. We found that compared to patients with inflammatory OAS, those with neoplastic OAS in this observation exhibited more diffuse lesions, involving adjacent tissue structures, and a significantly higher proportion of bone destruction. However, some cases of OAS caused by non-neoplastic causes can also present with space-occupying tumor-like lesions on imaging. Such lesions are most commonly attributed to non-infectious inflammatory etiologies (e.g., idiopathic orbital inflammatory pseudotumor). This phenomenon is essentially due to tissue fibrosis and granulation tissue proliferation induced by chronic inflammatory stimulation, rather than abnormal cell proliferation of true tumors. Differential diagnosis from tumor-induced OAS can be achieved by combining response to empirical glucocorticoid therapy, and pathological biopsy results. In this observation, 17 cases with inflammatory OAS exhibited lesion imaging similar to those of neoplastic lesions, with 12 experienced biopsy to get a definitive diagnosis. Moreover, imaging examinations rechecked during follow-up also provide more support information for us to evaluate the next treatment plan: whether to continue immunotherapy, the drug reduction or withdrawal plan, whether surgical intervention is needed, and so on. Aryasit et al. [15] reported CCF as the leading cause in 80 OAS patients. Another study on 20 cases from southern Taiwan, China, found that malignant neoplasms were the leading cause of OAS, accounting for more than half of the cases [16]. The results of our study were extremely different from previous findings, in which inflammatory causes accounted for more than half of the cases (54.55%). Moreover, the inflammations leading to OAS in our study were mostly THS (41.67%) and nonspecific inflammation (41.67%). This disparity in results might be related to ethnicity, race, or regional differences in the incidence rate of related diseases. Moreover, it might also be related to the fact that this study was a single-center study, introducing systematic biases. Therefore, multicenter clinical studies with large sample sizes are needed to further clarify the etiology of OAS. A meta-analysis of OAS revealed poor overall visual prognosis, with only 51.7% of patients experiencing improvement in vision despite various medical and surgical interventions [17]. Our study demonstrated that the overall visual prognosis of OAS was not satisfactory, with only 39.39% of patients experiencing improvement in vision. However, 30 patients (45.45%) still had BCVA < 20/200 despite vigorous multidisciplinary management. Still, 39.39% of the patients experienced varying degrees of relief in their visual function. We found a significant reduction in proportion of patients with severe visual impairment (BCVA < 20/200) after treatment (63.64% vs. 45.45%, P = 0.036). Meanwhile, this proportion of severe visual impairment dropped from 55.56% to 27.78% in patients with inflammatory (P = 0.017). Our data showed a relationship between the inflammatory causes of the disease and visual prognosis; inflammatory causes might be correlated with better final visual acuity (P = 0.002). Subsequently, in the subgroup analysis, we found that patients in the inflammatory group were statistically younger, had a much shorter course of disease, and achieved better BCVA outcomes. However, after multivariate regression analysis, we found that patients with inflammatory OAS had a significantly higher probability of improvement than those with neoplasm. While gender, age, disease duration, and BCVA before treatment showed no significant effects on patient improvement. Upon analyzing the reasons, we believe that the disease is related to the clinical characteristics of inflammatory lesions. Inflammatory causes of OAS are managed via a multidisciplinary approach with systemic immunomodulatory agents, including corticosteroids, cyclophosphamide, methotrexate, and azathioprine [18]. Decompression surgery is reserved for alleviating tension on the optic nerve [18]. However, no improvement in visual function was observed for more than half of the patients with inflammation-induced OAS, with 10 patients having BCVA < 20/200. This might be attributed to not only severe damage to visual function in patients enrolled in this study but also the long duration (mean 1.77 ± 0.89 months) before presentation. Literature confirms that OAS associated with non-specific inflammation carries a significantly better prognosis compared to tumor-induced or infectious OAS. Unlike irreversible neural damage caused by invasive tumor growth or infectious tissue necrosis, non-specific inflammation primarily involves reversible compression and edema. With standardized glucocorticoid therapy, symptoms such as orbital pain and ophthalmoplegia resolve rapidly, with superior recovery of ocular motility and visual function, and a lower recurrence rate. Early steroid administration effectively controls inflammation and protects optic nerve function, representing a key factor in improving outcomes [14]. Patients who received treatment within 72 h of onset had a significantly higher rate of optic nerve function recovery.In contrast, patients with a disease course exceeding 1 month or pre-treatment optic atrophy had poor visual recovery outcomes [9, 19]. In summary, the stratified management of inflammatory OAS, based on the type of etiology and the severity of the disease, combined with dynamic follow-up monitoring, can maximize the therapeutic effect, reduce drug side effects, and effectively protect optic nerve function. This management model is consistent with the clinical diagnosis and treatment concept of personalized medicine, and provides a reliable basis for the standardized treatment of inflammatory OAS [1, 10]. It should be noted that neoplastic OAS is significantly different from inflammatory OAS in terms of etiology, clinical manifestations, and treatment strategies. Early identification of the etiology and implementation of targeted treatment are the keys to improving the prognosis of patients [9, 14]. For IgG4-related OAS, only 2 cases in this study although, early diagnosis based on comprehensive evaluation of clinical, laboratory, imaging, and pathological findings, and timely implementation of stratified glucocorticoid combined with immunosuppressant treatment, can effectively alleviate inflammatory infiltration, protect optic nerve function, and reduce the risk of disease recurrence and systemic organ involvement [20, 21]. Conclusions OAS has multiple causes, varying from inflammatory disorders to neoplasms, vascular conditions, trauma, and infection. A careful clinical examination, comprehensive systemic work-up, and imaging are essential to establish the diagnosis and start adequate treatment. Most patients with OAS experience severe vision loss despite multidisciplinary management. Hence, establishing the underlying etiology of this syndrome is particularly important. Patients with inflammatory OAS may have more favorable outcomes. We believe that our data can help ophthalmologists and neuro-ophthalmologists in avoiding misdiagnosis or delayed treatment. Limitations Our study had several limitations. First, our study was based on data from a tertiary referral center. Therefore, the patients tended to have more severe visual impairment and complexity, contributing to an overall poor prognosis. Pediatric patients were not included in the scope of this study. Therefore, the findings in our study population may not be generalizable to the entire population. Further studies involving multiple medical centers and larger sample sizes are necessary to overcome these limitations. Second, selection bias should be acknowledged in this study. A total of 66 patients were enrolled as research subjects from the initial cohort of 126 OAS patients, which may inevitably lead to selection bias. The potential causes of this bias is that the enrolled cases were probably selected based on the completeness of clinical data (e.g., complete follow-up records, detailed records of imaging), while patients with missing key data were excluded, which may lead to the underrepresentation of some subgroups with incomplete data. In terms of the impact of this bias on the research results, since the enrolled patients were relatively homogeneous in clinical data completeness, the statistical differences in age, disease course and BCVA outcomes between the two subgroups may be overestimated to a certain extent, but the non-significant differences in clinical manifestations (extraocular muscle palsy, facial paresthesia, pain) were less affected. In addition, the limited sample size after selection may reduce the statistical power of the study, especially for the multivariate regression analysis, which may lead to the failure to detect some potential confounding factors. To minimize the impact of selection bias in future studies, a prospective cohort study design is recommended, in which all consecutive OAS patients are enrolled without selective exclusion to ensure the representativeness of the sample. Meanwhile, sensitivity analysis can be added to verify the stability of the research results by comparing the data of enrolled patients and excluded patients. Acknowledgements Not applicable. Abbreviations Orbital apex syndrome Cranial nerves Magnetic resonance imaging Computed tomography Visual field No light perception Antineutrophil cytoplasmic antibodies Lumbar puncture Cerebrospinal fluid Optical coherence tomography Author contributions Zhonghua Ma and Hanqiu Jiang carried out the studies, participated in collecting data, and drafted the manuscript. Shilei Cui and Jingting Peng performed the statistical analysis and participated in its design. Jiawei Wang and Zhonghua Ma participated in acquisition, analysis, or interpretation of data and draft the manuscript. All authors read and approved the final manuscript. Funding Not applicable. Data availability All data generated or analysed during this study are included in this published article. Declarations Ethics approval and consent to participate The study was approved by the Institutional Review Board of Beijing Tongren Hospital, Capital Medical University (TRECKY2021-046). All participants were informed about the study protocol and provided written informed consent to participate in the study. I confirm that all methods were performed in accordance with the relevant guidelines. All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analysed during this study are included in this published article.